| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13123* | 2021 |
| Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities E Jonasch, FG Haluska The oncologist 6 (1), 34-55, 2001 | 719 | 2001 |
| Renal cell carcinoma E Jonasch, J Gao, WK Rathmell Bmj 349, 2014 | 665 | 2014 |
| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672, 2021 | 663 | 2021 |
| Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, S Bhayani, WP Bro, SS Chang, ... Journal of the National Comprehensive Cancer Network 15 (6), 804-834, 2017 | 554 | 2017 |
| Kidney cancer RJ Motzer, N Agarwal, C Beard, GB Bolger, B Boston, MA Carducci, ... Journal of the National Comprehensive Cancer Network 7 (6), 618-630, 2009 | 425 | 2009 |
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma L Zhou, XD Liu, M Sun, X Zhang, P German, S Bai, Z Ding, N Tannir, ... Oncogene 35 (21), 2687-2697, 2016 | 394 | 2016 |
| Belzutifan for renal cell carcinoma in von Hippel–Lindau disease E Jonasch, F Donskov, O Iliopoulos, WK Rathmell, VK Narayan, ... New England Journal of Medicine 385 (22), 2036-2046, 2021 | 356 | 2021 |
| The PI3K/AKT pathway and renal cell carcinoma H Guo, P German, S Bai, S Barnes, W Guo, X Qi, H Lou, J Liang, ... Journal of genetics and genomics 42 (7), 343-353, 2015 | 342 | 2015 |
| Clear cell renal cell carcinoma ontogeny and mechanisms of lethality E Jonasch, CL Walker, WK Rathmell Nature Reviews Nephrology 17 (4), 245-261, 2021 | 336 | 2021 |
| Everolimus versus sunitinib prospective evaluation in metastatic non–clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial NM Tannir, E Jonasch, L Albiges, E Altinmakas, CS Ng, SF Matin, X Wang, ... European urology 69 (5), 866-874, 2016 | 336 | 2016 |
| Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ... Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022 | 329 | 2022 |
| Follow-up for clinically localized renal neoplasms: AUA guideline SM Donat, M Diaz, JT Bishoff, JA Coleman, P Dahm, IH Derweesh, ... The Journal of urology 190 (2), 407-416, 2013 | 307 | 2013 |
| Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial BI Rini, B Melichar, T Ueda, V Grünwald, MN Fishman, JA Arranz, AH Bair, ... The lancet oncology 14 (12), 1233-1242, 2013 | 257 | 2013 |
| Kidney cancer, version 3.2015 RJ Motzer, E Jonasch, N Agarwal, C Beard, S Bhayani, GB Bolger, ... Journal of the National Comprehensive Cancer Network 13 (2), 151-159, 2015 | 255 | 2015 |
| Dual chromatin and cytoskeletal remodeling by SETD2 IY Park, RT Powell, DN Tripathi, R Dere, TH Ho, TL Blasius, YC Chiang, ... Cell 166 (4), 950-962, 2016 | 226 | 2016 |
| The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) BI Rini, D Battle, RA Figlin, DJ George, H Hammers, T Hutson, E Jonasch, ... Journal for immunotherapy of cancer 7, 1-20, 2019 | 220 | 2019 |
| SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development Q Xu, Y Xiang, Q Wang, L Wang, J Brind’Amour, AB Bogutz, Y Zhang, ... Nature genetics 51 (5), 844-856, 2019 | 214 | 2019 |
| Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma E Jonasch, CG Wood, SF Matin, SM Tu, LC Pagliaro, PG Corn, A Aparicio, ... Journal of clinical oncology 27 (25), 4076, 2009 | 214 | 2009 |
| Testicular cancer RJ Motzer, N Agarwal, C Beard, GB Bolger, B Boston, MA Carducci, ... Journal of the National Comprehensive Cancer Network 7 (6), 672-693, 2009 | 213 | 2009 |
